

REMARKS

Upon entry of the forgoing amendment, claims 28-50 and 76-80 are pending. Claims 1-27 and 51-75 are cancelled without prejudice or disclaimer. New claims 76-80 are added. Support for new claims 76-80 can be found in the specification, for example, at page 21, paragraph [067].

In response to the Restriction Requirement, Applicants elect Group II without traverse. Claims 28-50 correspond with Group II.

Additionally, Applicants elect the species of:

(a) The single modifies glycoprotein hormone of follicle stimulating hormone (FSH) with the following amino acid substitutions Q13R, E14R, P16R, and Q20R as encompassed by claims 28, 30, 37-50 and new claims 76-80.

(b) The single disease state of ovarian cancer. Claims 28-50 and 76-80 are readable on this species.

(c) The single agent of doxorubin. Claims 28-39, 50 and 76-80 are readable on this species.

Applicants understand that upon a finding of patentability of the elected species listed above, the Examiner will open examination to additional species

In view of the foregoing, Applicant respectfully submits that no further impediments exist to the examination of this application. However, the Examiner is requested to call the undersigned if any questions or comments arise.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 50-1283.

Dated:


June 16, 2010

COOLEY LLP
ATTN: Patent Group
777 6th Street NW, Suite 1100
Washington, DC 20001

Tel: (202) 728-7129
Fax: (202) 842-7899

Respectfully submitted,
COOLEY LLP

By:


Alyson C. Fuller
Reg. No. 61,844